Junshi Biosciences invests in Beijing GRIT Biotechnology, boosting innovation in pharma

Shanghai Junshi Biosciences Co., Ltd. has announced a strategic external investment and related party transaction. Its controlling subsidiary, JunTop Biosciences, will subscribe to 1,280,623 shares in Beijing GRIT Biotechnology Co., Ltd. for RMB80 million. This investment will result in Junshi Biosciences and JunTop Biosciences jointly holding 5.1105% equity in Beijing GRIT upon completion.

Additionally, Shanghai Tanying Investment Partnership (LP), a shareholder of Junshi Bio holding over 5% of its shares, will subscribe to 640,311 shares in Beijing GRIT for RMB40 million. This constitutes a related party transaction. The pre-investment valuation for this round of financing for Beijing GRIT was RMB1.45 billion.

The board of directors approved the transaction on September 29, 2025, noting it aligns with the company's long-term development strategy and is not expected to materially impact operating results. Beijing GRIT specializes in immunotherapy, focusing on Tumor Invasion Lymphocytes (TIL) drugs, with projects such as GT101 and GT201 in clinical trials.